WO1990010715A1 - In-situ hybridization in suspension for detection or separation of cells - Google Patents
In-situ hybridization in suspension for detection or separation of cells Download PDFInfo
- Publication number
- WO1990010715A1 WO1990010715A1 PCT/US1990/001191 US9001191W WO9010715A1 WO 1990010715 A1 WO1990010715 A1 WO 1990010715A1 US 9001191 W US9001191 W US 9001191W WO 9010715 A1 WO9010715 A1 WO 9010715A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- probe
- cells
- cell
- suspended
- nucleic acid
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title abstract description 14
- 238000001514 detection method Methods 0.000 title description 10
- 238000007901 in situ hybridization Methods 0.000 title description 9
- 238000000926 separation method Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 71
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 38
- 239000000523 sample Substances 0.000 claims description 74
- 239000002773 nucleotide Substances 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 38
- 108020004707 nucleic acids Proteins 0.000 claims description 33
- 102000039446 nucleic acids Human genes 0.000 claims description 33
- 238000009396 hybridization Methods 0.000 claims description 29
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 238000000684 flow cytometry Methods 0.000 claims description 14
- 230000000295 complement effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 8
- 229920002866 paraformaldehyde Polymers 0.000 claims description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 239000002751 oligonucleotide probe Substances 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 6
- 238000000386 microscopy Methods 0.000 claims description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 3
- 239000002853 nucleic acid probe Substances 0.000 claims 3
- 230000000415 inactivating effect Effects 0.000 claims 1
- 108020004414 DNA Proteins 0.000 abstract description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract description 13
- 230000008569 process Effects 0.000 abstract description 3
- 108091092356 cellular DNA Proteins 0.000 abstract description 2
- 108091092328 cellular RNA Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 124
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 15
- 239000000872 buffer Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 238000004163 cytometry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000834 fixative Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- 210000001822 immobilized cell Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001047 purple dye Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JTNGEYANGCBZLK-UHFFFAOYSA-N 1h-indol-3-yl dihydrogen phosphate Chemical compound C1=CC=C2C(OP(O)(=O)O)=CNC2=C1 JTNGEYANGCBZLK-UHFFFAOYSA-N 0.000 description 1
- CZIHNRWJTSTCEX-UHFFFAOYSA-N 2 Acetylaminofluorene Chemical compound C1=CC=C2C3=CC=C(NC(=O)C)C=C3CC2=C1 CZIHNRWJTSTCEX-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- NFOMHWALMFWNAQ-UHFFFAOYSA-N N-acetoxy-2-acetamidofluorene Chemical compound C1=CC=C2C3=CC=C(N(C(C)=O)OC(=O)C)C=C3CC2=C1 NFOMHWALMFWNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
Definitions
- This invention relates generally to nucleic acids and more specifically to techniques for hybridizing and detecting nucleic acid sequences within a cell while the cell is in suspension.
- Complementary strands of nucleic acid such as DNA or RNA can form a double-stranded molecule linked by complementary bases in a process known as hybridization.
- Hybrids may be formed between any two complementary strands, so hybrids of DNA:DNA are possible, as are DNA:RNA and RNA:RNA.
- the reaction is reversible under particular temperature and salt concentration conditions.
- nucleic acids are first isolated and then permitted to hybridize with particular labelled nucleotide sequences termed probes. While such nucleic acid hybridization is well known in the art, methods for hybridization of nucleic acid sequences within cells in suspension have not been available.
- in situ hybridization has been used to detect DNA sequences within suspended nuclei removed from cells, Trask, B., et al., Science, 230:1401-03, (1985), Trask, B. , et al.. Human Genetics, 78:251-59 (1988), Van der Engh, G.J. and Trask, B.J. (1988), U.S. Patent No. 4,770,992.
- Trask, et al. cross-linked nuclei, isolated from cells, with dimethylsuberimidate to prevent disintegration of the nuclei during denaturation and hybridization.
- AAF N-acetoxy-2-acetylaminofluorene
- AAIF iodinated analog
- biotin-labelled chromosomal and cloned DNA probes were hybridized to their respective targets and the probes detected with anti-AAF or anti-AAIF antibodies and a secondary rhodamine-labelled antibody (for AAF- or AAIF-labelled probes) or fluorescein-avidin-DSC (for biotin-labelled probes) by flow cytometry.
- Flow cytometry is a technique for rapidly sorting individual cells, microorganisms and cell organelles into groups based on observable differences. Briefly summarized, the technique involves passing a stream of material to be measured (cells, lysed cells or other material) in single file past a light source where the particular property is detected, usually based on the reaction of the light to the materials. A computer then directs the separation of the material as desired. This technique is very rapid and allows separation of from 10 4 to 10 6 cells per minute.
- Fluorochromes are most often used to label the cellular component of interest before passing the cell sample past the light source.
- a variety of fluorochromes have been used to nonspecifically stain DNA, RNA and proteins for cytometric analysis.
- Immunological techniques have been used to detect cell surface markers and cell interior markers specifically with fluorescent antibodies.
- Nonfluorescent dyes can also be utilized in this system.
- Cells can absorb light as they pass through a focused light beam, and light transmitted by cells stained with nonfluorescent dyes can be quantitated and related to analyte concentration. This technique can help measure the expression of various target molecules in cells.
- a suinmary of flow cytometry as a technique is provided in Muirhead, K.A. , et al., Biotechnology, 3:337- 56 (1985).
- the present invention provides a technique for the hybridization of nucleotide probes to nucleic acids within a cell while the cell remains in suspension.
- the technique comprises fixing the suspended cell, hybridizing the nucleic acid within the cell with an oligonucleotide probe and detecting the hybridized probe.
- the nucleic acid can be denaturated prior to hybridization and endogenous enzymes can be ablated.
- the invention also provides a technique for categorizing cells by flow cytometry based on differences in target nucleic acid sequence. Additional objects and advantages of the invention will be apparent to those skilled in the art upon reading the specification and claims.
- a cell suspended in fluid having a hybridized nucleotide probe therein is also provided as well as a kit for detecting a specific nucleotide sequence in a cell suspended in a fluid.
- the kit comprises a means for fixing the suspended cell and a nucleotide probe complementary to a nucleotide sequence within the suspended cell.
- the kit can also include a means for detecting the hybridized probe.
- a method for detecting a specific nucleotide sequence in the nucleic acid in a cell suspended in a fluid comprises (l) fixing the suspended cell in such a way as to permit a nucleotide probe to penetrate without disrupting the suspended cell, (2) providing a nucleotide probe complementary to the specific nucleotide sequence within the suspended cell under conditions permitting hybridization, and (3) detecting hybridized probe within the cell, whereby hybridized probe indicates the presence of the specific nucleotide sequence.
- the method can include the further step of denaturing the nucleic acid before hybridizing with a nucleotide probe or ablating endogenous enzymes.
- probe or nucleotide probe refers to a labelled nucleotide sequence.
- the nucleotides can be deoxyribonucleotides or ribonucleotides.
- the number of nucleotides present in the probe is variable, depending on the application. Preferably, the range is between 10 and 2000 nucleotides, more preferably between 15 and 50, most preferably 20 to 25.
- oligonucleotide refers to nucleotide sequences less than 200 residues in length.
- Various labels are well known in the art and include fluorophores, enzymes, and radioactive isotopes, haptens and other ligands.
- probes are described, for example, in PCT Publication No. WO 84/03285.
- the probe can be a single selected homogeneous sequence or can be a mixture of various selected sequences.
- a mixture can be used, for example, to increase the sensitivity of the assay or to permit detection even where a portion of the nucleic acid in the target cell is variant, as a result, for example, of genetic alteration.
- the present invention is useful for detecting a target nucleic acid sequence in a single cell in suspension.
- the technique may be achieved using automatic flow analysis, for example, flow cytometry.
- the technique involves manufacturing oligonucleotides by methods known in the art. See, for example. United States Patent No. 4,500,707 Matteucci and Caruthers, (1981), J. Am. Chem. Soc., 103:3185-3191, which is incorporated herein by reference. These oligonucleotides are then labelled with enzymes, fluorophores or ligands (molecules with high affinity for other molecules) , also by means known in the art. See, for example Jablonski, E.G., et al.
- oligonucleotides may be used as probes for hybridization with DNA or RNA in the nucleus or in the cytoplasm of cells. The presence of hybridized cellular DNA or RNA is then established by detecting the label on the probe.
- the ji situ hybridization assay set forth here may be used in tandem with flow cytometry to assist for example in the diagnosis of various agents that infect or invade cells (viruses, chlamydia, certain bacteria and certain parasites) and to diagnose cancer and genetic diseases.
- Detection by microscopic analysis can be used in place of flow cytometry, but flow cytometry is preferred.
- the technique of the present invention may be combined with flow cytometry to form an automated, rapid detection or quantitation system for use in hospitals and research laboratories.
- the technique of the present invention may also be used separately and the labelled cells may be detected in a subsequent step, if desired.
- a technique of the present invention may be briefly summarized as follows: (1) oligonucleotide probes are synthesized and labelled with enzymes, fluorophores, ligands or other detectable labels; (2) the probes are then hybridized with DNA or RNA in a fixed suspended cell, using the methods set out below; (3) the labels in the cells are detected using known optical techniques; and (4) the cells are separated, if desired.
- synthetic probes preferably DNA are prepared using conventional techniques.
- the probes are designed to be complementary to particular nucleotide sequences, termed target sequences of nucleic acids within the fixed cell.
- the selection of nucleotide sequence of the probe is within the skill and choice of those in the art.
- long chain probes greater than 200 nucleotides
- synthetic oligonucleotide probes (10 to 200 nucleotides, preferably 15 to 50 nucleotides) are preferred. Since higher concentrations of oligonucleotide probes can be used in the technique of the invention, maximum hybridization can usually occur within a short time, for example, ten minutes or less.
- oligonucleotides may be labelled directly, while long probes must typically be labelled indirectly, adding complexity and expense to the process but without providing significant additional reliability.
- a directly labelled probe is one where the label to be detected is directly attached to the probe.
- An indirectly labelled probe is one which has attached to it a moiety through which the label to be detected is subsequently attached. Additionally, short probes can more easily permeate cells than can longer probes.
- labels include enzymes, fluorophores and ligands. Other labels are available and are well known in the art. Enzyme labels include alkaline phosphatase, horseradish peroxidase, ⁇ -galactosidase, glucose oxidase and luciferase. Fluorophores include fluorescein and Texas Red.
- Ligand labels include biotin, digoxigenin, AAF and AAIF.
- Protected linker arm nucleoside 3'-phosphoramidite was prepared by the method of Ruth, J. DNA, 3:123 (1984) .
- linker arm monomer was incorporated directly into automated oligonucleotide synthesis employing an Applied source
- the preferred conditions for nucleic acid denaturation is a combination of heat 50 e C to 100°C, preferably 65°-70°C, and a formamide concentration of 40% to 100%, preferably about 70% ultrapure: 30% low salt buffer) .
- the hybridization technique is useful for in situ hybridization within cells in suspension. Before hybridization can occur, the cell must be fixed. Fixation is the chemical preservation of cells or tissue so that the structure will be minimally altered from the normal state. There are generally two types of fixatives, crosslinking (for example, parafor aldehyde, glutaraldehyde) and precipitating (alcohols) .
- fixatives for example, parafor aldehyde, glutaraldehyde
- precipitating alcohols
- fixation with paraformaldehyde is preferred, although other crosslinking fixatives will achieve effective results.
- the preferred amount of paraformaldehyde is between 0.5% and 5%. Precipitating fixatives are less desirable, as cell morphology is not well maintained and cells tend to clump.
- nucleic acid within the cells can be denatured.
- Denaturing agents or conditions for nucleic acid include formamide, glyoxal, heat (90°C to 100 ⁇ C, preferably 0 to 0.3M salt concentration), acid or base (DNA only) treatments. Denaturation with a combination of heat (>65 ⁇ C) and formamide (both DNA and RNA denaturation) is preferred. Where the secondary structure of the nucleic acid does not provide a barrier to hybridization, for example where the nucleic acid is shorter, single stranded RNA or where the probe is short and recognizes an exposed sequence, denaturation is not necessarily required.
- probe in hybridization buffer is added immediately and hybridization commences.
- Conditions for hybridization depend on probe base content. Hybridization can occur in the presence or absence of formamide ( ⁇ 40%) and in a temperature range of ambient temperature (23 ⁇ C) to 75°C for alkaline phosphatase probes; the temperature and formamide concentration are experimentally determined. Washing of unreacted or loosely bound probe from cells occurs at a temperature and salt concentration which are likewise experimentally determined (23-75°C, ⁇ 0.3M) .
- Detection of alkaline phosphatase labelled probe hybridized to its complement in cells occurs preferably with the addition of NBT and BCIP substrates, although other substrates (especially substrates which give insoluble products) can also be utilized. A red to purple product is desired.
- In situ hybridization of cells, accomplished in suspension is well adapted to automation and thus is highly desirable for applications where a complete automated system is preferable, for example, for clinical diagnostic purposes.
- Cytomegalovirus (CMV)-infected and uninfected human fetal foreskin fibroblast (HFFF) cells were treated with 0.5% paraformaldehyde in phosphate-buffered saline (PBS) , a common buffer, for one minute at 60°C. Treating for ten minutes at ambient temperature (23°C) was an acceptable alternative.
- PBS phosphate-buffered saline
- the fixed cells were suspended for two minutes at room temperature with 0.2N HC1.
- the nucleic acids within the suspended cells were denatured with a mixture of 70% formamide (ultrapure) and 30% 2X SSC (0.3M sodium chloride, 0.03M sodium citrate, pH 7.0) for 10 minutes at 70-C.
- Hybridization buffer contains 5X SSC (0.75 sodium chloride, 0.075M sodium citrate, pH 7.0), combined with 0.5% bovine serum albumin (BSA, Fraction V). Alternatively, the cells and probe were mixed with 30% formamide in 70% hybridization buffer at 37°C for ten minutes.
- CMV sequences are available from GenBank, (IntelliGenetics, Mountain View, CA) Accession Nos. K01090, M10063, M11911) . The following nucleotide sequences were used as probes:
- Substrate was added to cells so that the labelling enzyme was detected.
- BCIP 3-indolylphosphate
- AP alkaline phosphatase buffer
- 0.1M Tris-HCl, pH 8.5; 0.1M NaCl, 0.05M MgCl 2 ; and O.l ⁇ tM ZnCl 2 was pre-warmed to 37°C and added to the cells. Incubation took place for 1.0 hour, during which time the enzyme label converted the substrate to an insoluble purple dye.
- the cells were rinsed with distilled water and were ready for analysis and/or separation by acceptable methods, including cell cytometry. Cells positive for virus turned an opaque blue-purple, while uninfected cells remained colorless.
- HIV Human immunodeficiency virus
- CEM cells peripheral blood mononuclear cells
- the fixed cells were suspended for two minutes at room temperature in 0.2N HC1.
- the nucleotides in the suspended cells were denatured with a mixture of 70% formamide (ultrapure) and 30% 2X SSC for 10 minutes at 70°C.
- the cells were immediately hybridized by placing them in hybridization buffer with a mixture of twenty 2.5 nM alkaline phosphatase-labelled probes (20-24 bases) specific for HIV for ten minutes at 55"C. HIV sequences are available from GenBank, Accession number K03455. Labelling was as described in Example I. Excess probe was washed out of the cells three times, with IX SSC at 45°C.
- Substrate was added to cells so that the labelling enzyme was detected.
- a 1 ml solution of 0.33 mg/ml nitro blue tetrazolium (NBT) and 0.17 mg/ml 5-bromo-4-chloro- 3-indolylphosphate (BCIP) in alkaline phosphatase (AP) buffer was pre-warmed to 37°C and added to the cells. Incubation took place for 0.5 hours, during which time the enzyme label converted the substrate to an insoluble purple dye.
- the cells were rinsed with distilled water and were ready for analysis and/or separation by acceptable methods, including cell cytometry. Cells positive for virus turned an opaque blue-purple, while uninfected cells remained colorless.
- Herpes simplex virus type 1 (HSV)-infected and uninfected HEp-2 cells were treated with 0.5% paraformaldehyde in PBS for one minute at 60°C. The fixed cells were then suspended for two minutes at room temperature in 0.2N HC1. The cells were further treated, in suspension, with 0.01% hydrogen peroxide in methanol for 20 minutes at ambient temperature.
- HSV Herpes simplex virus type 1
- the nucleic acids in the cells were denatured with a mixture of 70% formamide (ultrapure) and 30% 2X SSP (0.36M NaCl, 20 mM NaH 2 P0 4 , pH 7.0) 10 minutes at 70°C.
- the cells were immediately hybridized by placing them in "hybridization buffer II" with 5 nM horseradish peroxidase-labelled 22 base probe specific for HSV1 and HSV2 for ten minutes at 50°C.
- the HSV sequence is available from GenBank, Accession No. J02224.
- Hybridization buffer II contained 5X SSP (0.9M NaCl; 50 mM NaH 2 P0 4 , pH 7.0) and 0.5% BSA (Fraction V). Excess probe was washed out of the cells three times, with IX SSP (0.18M NaCl; lOmM NaH 2 P0 4 , pH 7.0) at 50°C.
- Substrate was then added to the cells so that the labelling enzyme could be detected.
- a 1 ml solution of 0.5 mg/ml 0-dianisidine dihydrochloride in HRP buffer (0.1M imidazole, 0.1M NaCl, pH 7.4 with 0.001% hydrogen peroxide) was added to the cells. Incubation took place for 1.0 hour at ambient temperature, during which time the enzyme label converted the substrate to an orange dye.
- the cells were rinsed with distilled water and were ready for analysis and/or separation by acceptable methods, including cell cytometry. Cells positive for virus turned orange, while uninfected cells remained colorless.
- Herpes simplex virus (HSV)-infected and uninfected HEp-2 cells are treated with 0.5% paraformaldehyde in PBS. The fixed cells are then suspended for two minutes at room temperature with 0.2N HC1. The suspended cells are denatured with a mixture of 70% formamide (ultrapure) and 30% 2X SC for 10 minutes at 70°C. The cells are immediately hybridized in hybridization buffer with six 5 nM Texas Red-labelled and (separately) six fluorescein-labelled 22-25 base probes specific for HSV1 and HSV2 for ten minutes at 60°C.
- hybridization buffer with six 5 nM Texas Red-labelled and (separately) six fluorescein-labelled 22-25 base probes specific for HSV1 and HSV2 for ten minutes at 60°C.
- oligonucleotides were labelled via the linker arm with isothiocyanate or sulfonyl chloride derivatives of either Texas Red or fluorescein by the method of PCT Publication No. WO 84/03285.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
A process is provided for detecting nucleic acid sequences within a cell in suspension. A technique for directly hybridizing labelled deoxyoligonucleotides with cellular DNA or RNA sequences contained in suspended, intact cells is disclosed along with techniques for separating cells containing hybridized DNA or RNA from cells that do not contain hybridized DNA or RNA.
Description
IN-SITU HYBRIDIZATION IN SUSPENSION
FOR DETECTION OR SEPARATION OF CELLS
BACKGROUND OF THE INVENTION
This invention relates generally to nucleic acids and more specifically to techniques for hybridizing and detecting nucleic acid sequences within a cell while the cell is in suspension.
Complementary strands of nucleic acid such as DNA or RNA can form a double-stranded molecule linked by complementary bases in a process known as hybridization. Hybrids may be formed between any two complementary strands, so hybrids of DNA:DNA are possible, as are DNA:RNA and RNA:RNA. The reaction is reversible under particular temperature and salt concentration conditions. Most often, nucleic acids are first isolated and then permitted to hybridize with particular labelled nucleotide sequences termed probes. While such nucleic acid hybridization is well known in the art, methods for hybridization of nucleic acid sequences within cells in suspension have not been available.
In situ hybridization of nucleic acid in cells affixed to slides and coverslips has been described by Gall, J. and Pardue, M. , Proc. Nat. Acad. Sci. , (USA), 63:378-83 (1969). These early attempts at in situ hybridization used, as probes, naturally occurring DNA or RNA purified from cells or cell supernatants and labelled with radioisotopes. Because of limited sensitivity, however, only highly reiterated, or amplified, genes were susceptible to the technique.
Nucleic acid hybridization techniques have since been simplified by using recombinant DNA or synthetic oligonucleotides as probes. See, for example, Venesky, D. et al., Cell, 24:385-391 (1981) and Montgomery, E. A., et al, Cell, 14:673-80 (1978). Labelling probes with nonradioactive compounds has further streamlined the methodology, Rudkin, G.T. and Stollar, B.D., Nature, 265:472-73, (1977), Langer, P. R. et al., Proc. Natl. Acad. Sci. (USA) 78:6633-37 (1981); Jablonski, et al., Nucleic Acids Research 14:6115-28 (1986).
In addition, in situ hybridization has been used to detect DNA sequences within suspended nuclei removed from cells, Trask, B., et al., Science, 230:1401-03, (1985), Trask, B. , et al.. Human Genetics, 78:251-59 (1988), Van der Engh, G.J. and Trask, B.J. (1988), U.S. Patent No. 4,770,992. Trask, et al. cross-linked nuclei, isolated from cells, with dimethylsuberimidate to prevent disintegration of the nuclei during denaturation and hybridization. N-acetoxy-2-acetylaminofluorene (AAF) , its iodinated analog AAIF, and biotin-labelled chromosomal and cloned DNA probes were hybridized to their respective targets and the probes detected with anti-AAF or anti-AAIF antibodies and a secondary rhodamine-labelled antibody (for AAF- or AAIF-labelled probes) or fluorescein-avidin-DSC (for biotin-labelled probes) by flow cytometry.
These methods of hybridizing isolated nucleic acid, or nucleic acid in immobilized cells or suspended nuclei, have various applications, for example in the detection of the presence of infectious agents. Nevertheless, such methods have serious limitations. For example, they do not allow the detection of nucleic acid in the cytoplasm
of the cells. Often only a small percentage of the cells in a sample contain the nucleotide sequence of interest. Detecting the presence of even a small number of infected cells can be of critical importance, however. Where the nucleic acid from a sample is isolated and pooled, the dilution by non-complementary sequences from uninfected cells can preclude detection of infected cells. On the other hand, where hybridization is performed on immobilized cells, detecting positive cells by microscopy can be burdensome, time-consuming, and unreliable.
Flow cytometry is a technique for rapidly sorting individual cells, microorganisms and cell organelles into groups based on observable differences. Briefly summarized, the technique involves passing a stream of material to be measured (cells, lysed cells or other material) in single file past a light source where the particular property is detected, usually based on the reaction of the light to the materials. A computer then directs the separation of the material as desired. This technique is very rapid and allows separation of from 104 to 106 cells per minute.
Fluorochromes are most often used to label the cellular component of interest before passing the cell sample past the light source. A variety of fluorochromes have been used to nonspecifically stain DNA, RNA and proteins for cytometric analysis. Immunological techniques have been used to detect cell surface markers and cell interior markers specifically with fluorescent antibodies.
Nonfluorescent dyes can also be utilized in this system. Cells can absorb light as they pass through a
focused light beam, and light transmitted by cells stained with nonfluorescent dyes can be quantitated and related to analyte concentration. This technique can help measure the expression of various target molecules in cells. A suinmary of flow cytometry as a technique is provided in Muirhead, K.A. , et al., Biotechnology, 3:337- 56 (1985).
It has been known for some time that DNA or RNA can be hybridized in cells which have been affixed to slides or another solid support. Further, it has been known that in situ hybridization may be used to detect DNA sequences within suspended nuclei removed from cells. Until now, however, methods for nucleic acid hybridization within cells in suspension had not been available. It was commonly believed that without the structural support of a slide or another solid matrix, cellular components would disintegrate during the rigorous hybridization procedures. See, for example, U.S. Patent No. 4,770,992. Moreover, even if the cells remain intact during the procedures, there is difficulty in both getting the probe inside the cell and nuclear membranes and washing unbound probe out of cells after hybridization.
There thus exists a long-felt need for methods to hybridize probes to nucleic acid in suspended cells. Such a method would be of particular use in conjunction with automated methods for identifying and separating cells, such as flow cytometry. The present invention satisfies this need and provides related advantages as well.
SUMMARY OF THE INVENTION
The present invention provides a technique for the hybridization of nucleotide probes to nucleic acids within a cell while the cell remains in suspension. The technique comprises fixing the suspended cell, hybridizing the nucleic acid within the cell with an oligonucleotide probe and detecting the hybridized probe. The nucleic acid can be denaturated prior to hybridization and endogenous enzymes can be ablated. The invention also provides a technique for categorizing cells by flow cytometry based on differences in target nucleic acid sequence. Additional objects and advantages of the invention will be apparent to those skilled in the art upon reading the specification and claims.
A cell suspended in fluid having a hybridized nucleotide probe therein is also provided as well as a kit for detecting a specific nucleotide sequence in a cell suspended in a fluid. The kit comprises a means for fixing the suspended cell and a nucleotide probe complementary to a nucleotide sequence within the suspended cell. The kit can also include a means for detecting the hybridized probe.
DETAILED DESCRIPTION OF THE INVENTION
A method is provided for detecting a specific nucleotide sequence in the nucleic acid in a cell suspended in a fluid. The method comprises (l) fixing the suspended cell in such a way as to permit a nucleotide probe to penetrate without disrupting the suspended cell, (2) providing a nucleotide probe complementary to the specific nucleotide sequence within
the suspended cell under conditions permitting hybridization, and (3) detecting hybridized probe within the cell, whereby hybridized probe indicates the presence of the specific nucleotide sequence. The method can include the further step of denaturing the nucleic acid before hybridizing with a nucleotide probe or ablating endogenous enzymes.
As used herein, the term probe or nucleotide probe refers to a labelled nucleotide sequence. The nucleotides can be deoxyribonucleotides or ribonucleotides. The number of nucleotides present in the probe is variable, depending on the application. Preferably, the range is between 10 and 2000 nucleotides, more preferably between 15 and 50, most preferably 20 to 25. As used herein, oligonucleotide refers to nucleotide sequences less than 200 residues in length. Various labels are well known in the art and include fluorophores, enzymes, and radioactive isotopes, haptens and other ligands. Methods for making such labelled probes are described, for example, in PCT Publication No. WO 84/03285. Where a probe is used to detect the presence of complementary sequences in a cell in suspension, the probe can be a single selected homogeneous sequence or can be a mixture of various selected sequences. A mixture can be used, for example, to increase the sensitivity of the assay or to permit detection even where a portion of the nucleic acid in the target cell is variant, as a result, for example, of genetic alteration.
The present invention is useful for detecting a target nucleic acid sequence in a single cell in suspension. The technique may be achieved using
automatic flow analysis, for example, flow cytometry. In one embodiment, the technique involves manufacturing oligonucleotides by methods known in the art. See, for example. United States Patent No. 4,500,707 Matteucci and Caruthers, (1981), J. Am. Chem. Soc., 103:3185-3191, which is incorporated herein by reference. These oligonucleotides are then labelled with enzymes, fluorophores or ligands (molecules with high affinity for other molecules) , also by means known in the art. See, for example Jablonski, E.G., et al. (1986), Nucleic Acids Research 14:6115-6128; Heller, M.J., et al. (1986), Fed. Proc. 45:1516; PCT Publication No. WO 84/03285, all of which are hereby incorporated by reference. These labelled oligonucleotides may be used as probes for hybridization with DNA or RNA in the nucleus or in the cytoplasm of cells. The presence of hybridized cellular DNA or RNA is then established by detecting the label on the probe.
The ji situ hybridization assay set forth here may be used in tandem with flow cytometry to assist for example in the diagnosis of various agents that infect or invade cells (viruses, chlamydia, certain bacteria and certain parasites) and to diagnose cancer and genetic diseases.
Detection by microscopic analysis can be used in place of flow cytometry, but flow cytometry is preferred. The technique of the present invention may be combined with flow cytometry to form an automated, rapid detection or quantitation system for use in hospitals and research laboratories. The technique of the present invention may also be used separately and the labelled cells may be detected in a subsequent step, if desired.
A technique of the present invention may be briefly summarized as follows: (1) oligonucleotide probes are synthesized and labelled with enzymes, fluorophores, ligands or other detectable labels; (2) the probes are then hybridized with DNA or RNA in a fixed suspended cell, using the methods set out below; (3) the labels in the cells are detected using known optical techniques; and (4) the cells are separated, if desired.
In accordance with the invention, synthetic probes, preferably DNA, are prepared using conventional techniques. The probes are designed to be complementary to particular nucleotide sequences, termed target sequences of nucleic acids within the fixed cell. The selection of nucleotide sequence of the probe is within the skill and choice of those in the art. Although long chain probes (greater than 200 nucleotides) can be used and may be more sensitive than shorter probes, synthetic oligonucleotide probes (10 to 200 nucleotides, preferably 15 to 50 nucleotides) are preferred. Since higher concentrations of oligonucleotide probes can be used in the technique of the invention, maximum hybridization can usually occur within a short time, for example, ten minutes or less. Moreover, oligonucleotides may be labelled directly, while long probes must typically be labelled indirectly, adding complexity and expense to the process but without providing significant additional reliability. A directly labelled probe is one where the label to be detected is directly attached to the probe. An indirectly labelled probe is one which has attached to it a moiety through which the label to be detected is subsequently attached. Additionally, short probes can more easily permeate cells than can longer probes.
Examples of labels include enzymes, fluorophores and ligands. Other labels are available and are well known in the art. Enzyme labels include alkaline phosphatase, horseradish peroxidase, β-galactosidase, glucose oxidase and luciferase. Fluorophores include fluorescein and Texas Red. Ligand labels include biotin, digoxigenin, AAF and AAIF.
Protected linker arm nucleoside 3'-phosphoramidite was prepared by the method of Ruth, J. DNA, 3:123 (1984) .
The linker arm monomer was incorporated directly into automated oligonucleotide synthesis employing an Applied
Biosystems Model 380A DNA synthesizer using the phosphoramidite chemistry on controlled pore glass as first described by Matteucci and Caruthers, Tetrahedron
Letters 21:719-722 (1980), which is incorporated herein by reference. The purified oligonucleotide was covalently cross-linked to alkaline phosphatase using the ho obifunctional reagent disuccinimidyl suberate through the reactive primary amine on the linker arm by the method of Jablonski et al.. Nucleic Acids Research,
24:6115-6128 (1986).
The preferred conditions for nucleic acid denaturation is a combination of heat 50eC to 100°C, preferably 65°-70°C, and a formamide concentration of 40% to 100%, preferably about 70% ultrapure: 30% low salt buffer) .
The hybridization technique is useful for in situ hybridization within cells in suspension. Before hybridization can occur, the cell must be fixed. Fixation is the chemical preservation of cells or tissue so that the structure will be minimally altered from the
normal state. There are generally two types of fixatives, crosslinking (for example, parafor aldehyde, glutaraldehyde) and precipitating (alcohols) . For suspension in situ hybridization, fixation with paraformaldehyde is preferred, although other crosslinking fixatives will achieve effective results. The preferred amount of paraformaldehyde is between 0.5% and 5%. Precipitating fixatives are less desirable, as cell morphology is not well maintained and cells tend to clump.
After cells are fixed, it may be necessary to ablate endogenous enzyme by treating cells with 0.2N HC1. Treating cells with acid destroys cellular enzymes which may act to turn over alkaline phosphatase substrates, in addition to further permeabilizing cells. In the course of fixation, the cell must be opened enough so that the probe can penetrate the cell, but not enough so that the nucleus and cytosol (including mRNA and viral RNA or DNA) will escape. In addition, unreacted probe can be washed out of the cell to remove background labels yet the cell must still be kept intact to analyze without removing the hybridized sequences.
After cells are fixed, nucleic acid within the cells can be denatured. Denaturing agents or conditions for nucleic acid include formamide, glyoxal, heat (90°C to 100βC, preferably 0 to 0.3M salt concentration), acid or base (DNA only) treatments. Denaturation with a combination of heat (>65βC) and formamide (both DNA and RNA denaturation) is preferred. Where the secondary structure of the nucleic acid does not provide a barrier to hybridization, for example where the nucleic acid is shorter, single stranded RNA or where the probe is short
and recognizes an exposed sequence, denaturation is not necessarily required.
After denaturation, if used, probe in hybridization buffer is added immediately and hybridization commences. Conditions for hybridization depend on probe base content. Hybridization can occur in the presence or absence of formamide (<40%) and in a temperature range of ambient temperature (23βC) to 75°C for alkaline phosphatase probes; the temperature and formamide concentration are experimentally determined. Washing of unreacted or loosely bound probe from cells occurs at a temperature and salt concentration which are likewise experimentally determined (23-75°C,<0.3M) . Detection of alkaline phosphatase labelled probe hybridized to its complement in cells occurs preferably with the addition of NBT and BCIP substrates, although other substrates (especially substrates which give insoluble products) can also be utilized. A red to purple product is desired. In situ hybridization of cells, accomplished in suspension, is well adapted to automation and thus is highly desirable for applications where a complete automated system is preferable, for example, for clinical diagnostic purposes.
To illustrate the technique of jLn situ hybridization of cells in suspension, the following examples are provided. These examples are intended to illustrate the invention rather than to limit its applicability.
EXAMPLE I
Cytomegalovirus (CMV)-infected and uninfected human fetal foreskin fibroblast (HFFF) cells were treated with
0.5% paraformaldehyde in phosphate-buffered saline (PBS) , a common buffer, for one minute at 60°C. Treating for ten minutes at ambient temperature (23°C) was an acceptable alternative.
The fixed cells were suspended for two minutes at room temperature with 0.2N HC1. The nucleic acids within the suspended cells were denatured with a mixture of 70% formamide (ultrapure) and 30% 2X SSC (0.3M sodium chloride, 0.03M sodium citrate, pH 7.0) for 10 minutes at 70-C.
The cells were then immediately hybridized by placing them in "hybridization buffer" with a mixture of four 2.5 nM alkaline phosphatase-labelled probes (20-22 bases) specific for CMV for ten minutes at 55°C. "Hybridization buffer" contains 5X SSC (0.75 sodium chloride, 0.075M sodium citrate, pH 7.0), combined with 0.5% bovine serum albumin (BSA, Fraction V). Alternatively, the cells and probe were mixed with 30% formamide in 70% hybridization buffer at 37°C for ten minutes.
CMV sequences are available from GenBank, (IntelliGenetics, Mountain View, CA) Accession Nos. K01090, M10063, M11911) . The following nucleotide sequences were used as probes:
1) 5- GGCGAAAAGAAGACGCGTGT 31
2) 51 TTCTATGGAGGTCAAAACAGCG 31 3) 5' TGGCCAAAGTGTAGGCTACAAT 31
4) 5' GGAAAGTCCGAATCCTACACAT 3'
Excess probe was washed out of the cells three times, for 2 minutes each, with IX SSC (0.15M sodium chloride, 0.015M sodium citrate, pH 7.0) and cells separated from wash by low speed centrifugation at 55°C. Alternatively, cells were washed three times with 0.5X SSC (0.075M sodium chloride, 0.0075M sodium citrate, pH 7.0) at 37°C.
Substrate was added to cells so that the labelling enzyme was detected. A 1 ml solution of 0.33 mg/ml nitro blue tetrazolium (NBT) and 0.17 mg/ml 5-bromo-4-chloro-
3-indolylphosphate (BCIP) in alkaline phosphatase (AP) buffer (0.1M Tris-HCl, pH 8.5; 0.1M NaCl, 0.05M MgCl2; and O.lπtM ZnCl2) was pre-warmed to 37°C and added to the cells. Incubation took place for 1.0 hour, during which time the enzyme label converted the substrate to an insoluble purple dye. The cells were rinsed with distilled water and were ready for analysis and/or separation by acceptable methods, including cell cytometry. Cells positive for virus turned an opaque blue-purple, while uninfected cells remained colorless.
EXAMPLE II
Human immunodeficiency virus (HIV) persistently infected and uninfected CEM cells (lymphoid cell line) were treated with 1.0% paraformaldehyde in PBS for ten minutes at ambient temperature. The fixed cells were suspended for two minutes at room temperature in 0.2N HC1. The nucleotides in the suspended cells were denatured with a mixture of 70% formamide (ultrapure) and 30% 2X SSC for 10 minutes at 70°C.
The cells were immediately hybridized by placing them in hybridization buffer with a mixture of twenty 2.5 nM alkaline phosphatase-labelled probes (20-24 bases) specific for HIV for ten minutes at 55"C. HIV sequences are available from GenBank, Accession number K03455. Labelling was as described in Example I. Excess probe was washed out of the cells three times, with IX SSC at 45°C.
Substrate was added to cells so that the labelling enzyme was detected. A 1 ml solution of 0.33 mg/ml nitro blue tetrazolium (NBT) and 0.17 mg/ml 5-bromo-4-chloro- 3-indolylphosphate (BCIP) in alkaline phosphatase (AP) buffer was pre-warmed to 37°C and added to the cells. Incubation took place for 0.5 hours, during which time the enzyme label converted the substrate to an insoluble purple dye. The cells were rinsed with distilled water and were ready for analysis and/or separation by acceptable methods, including cell cytometry. Cells positive for virus turned an opaque blue-purple, while uninfected cells remained colorless.
EXAMPLE III
Herpes simplex virus type 1 (HSV)-infected and uninfected HEp-2 cells were treated with 0.5% paraformaldehyde in PBS for one minute at 60°C. The fixed cells were then suspended for two minutes at room temperature in 0.2N HC1. The cells were further treated, in suspension, with 0.01% hydrogen peroxide in methanol for 20 minutes at ambient temperature.
The nucleic acids in the cells were denatured with a mixture of 70% formamide (ultrapure) and 30% 2X SSP
(0.36M NaCl, 20 mM NaH2P04, pH 7.0) 10 minutes at 70°C. The cells were immediately hybridized by placing them in "hybridization buffer II" with 5 nM horseradish peroxidase-labelled 22 base probe specific for HSV1 and HSV2 for ten minutes at 50°C. The HSV sequence is available from GenBank, Accession No. J02224. Purified oligonucleotide was covalently cross-linked to horseradish peroxidase by the method of Jablonski, et al., Nucleic Acids Research, 24:6115-6128 (1986), which is incorporated herein by reference. "Hybridization buffer II" contained 5X SSP (0.9M NaCl; 50 mM NaH2P04, pH 7.0) and 0.5% BSA (Fraction V). Excess probe was washed out of the cells three times, with IX SSP (0.18M NaCl; lOmM NaH2P04, pH 7.0) at 50°C.
Substrate was then added to the cells so that the labelling enzyme could be detected. A 1 ml solution of 0.5 mg/ml 0-dianisidine dihydrochloride in HRP buffer (0.1M imidazole, 0.1M NaCl, pH 7.4 with 0.001% hydrogen peroxide) was added to the cells. Incubation took place for 1.0 hour at ambient temperature, during which time the enzyme label converted the substrate to an orange dye. The cells were rinsed with distilled water and were ready for analysis and/or separation by acceptable methods, including cell cytometry. Cells positive for virus turned orange, while uninfected cells remained colorless.
EXAMPLE IV
Herpes simplex virus (HSV)-infected and uninfected HEp-2 cells are treated with 0.5% paraformaldehyde in PBS. The fixed cells are then suspended for two minutes at room temperature with 0.2N HC1.
The suspended cells are denatured with a mixture of 70% formamide (ultrapure) and 30% 2X SC for 10 minutes at 70°C. The cells are immediately hybridized in hybridization buffer with six 5 nM Texas Red-labelled and (separately) six fluorescein-labelled 22-25 base probes specific for HSV1 and HSV2 for ten minutes at 60°C. Purified oligonucleotides were labelled via the linker arm with isothiocyanate or sulfonyl chloride derivatives of either Texas Red or fluorescein by the method of PCT Publication No. WO 84/03285.
Excess probe is washed out of the cells three times, as before, with IX SSC at 50°C. Cells are ready for analysis and/or separation by acceptable methods, including cell cytometry. Cells positive for virus demonstrate, upon excitation, increased photon emission at the proper wavelength.
It will be readily apparent to those skilled in the art that the methods described in the Examples above may be readily automated. Methods of performing flow cytometry are well known, and various flow cytometers are commercially available. See, for example, Shapiro, H. M. , Practical Flow Cytometry, Alan R. Liss, Inc., New York (1988) , which is incorporated herein by reference. The hybridized cells may be fed directly into the entrance of flow cytometry instrument, for detection by fluorescence or by optical density, depending on the label used.
Those skilled in the art will recognize that alterations may be made to the invention described above without departing from the scope or spirits thereof.
Claims
1. A method of detecting a specific nucleotide sequence in nucleic acid in a cell suspended in a fluid, comprising:
a. fixing the suspended cell in such a way as to permit a nucleic acid probe to penetrate without disrupting the suspended cell;
b. providing a nucleic acid probe complementary to the specific nucleotide sequence within the suspended cell under conditions permitting hybridization; and
c. detecting hybridized probe within the cell, whereby hybridized probe indicates the presence of the specific nucleotide sequence.
2. The method of claim 1, further comprising the step of denaturing the nucleic acid before hybridizing with a nucleic acid probe.
3. The method of claim 1, further comprising the step of inactivating endogenous enzymes.
4. The method of claim 1, wherein the nucleic acid is DNA.
5. The method of claim 1, wherein the nucleic acid is RNA.
6. The method of claim 1, wherein the nucleotide probe is an oligonucleotide probe.
7. The method of claim 6, wherein the oligonucleotide probe is DNA.
8. The method of claim 6, wherein the oligonucleotide probe is RNA.
9. The method of claim 1, wherein the nucleotide probe is labelled with a detectable moiety.
10. The method of claim 9, wherein the detectable moiety is selected from the group consisting of enzymes, fluoropores, or ligands.
11. The method of claim 9, wherein the labelled hybridized nucleotide probe is detected by flow cytometry.
12. The method of claim 9, wherein the labelled hybridized nucleotide probe is detected by microscopy.
13. The method of claim 1, wherein the suspended cells are fixed with a composition comprising paraformaldehyde.
14. The method of claim 1, wherein the suspended cells are fixed with between .01% and 5% paraformaldehyde.
15. The method of claim 1, wherein the suspended cells are denatured with a composition comprising formamide.
16. The method of claim 15, wherein the formamide comprises between 40% and 100% of the composition.
17. The method of claim 1, wherein the fixing is carried out at a temperature between 23° and 75°C.
18. The method of claim 1, wherein the hybridizing is carried out at a temperature between 23° and 75"C.
19. A cell suspended in fluid having a hybridized nucleotide probe therein.
20. A kit for detecting a specific nucleotide sequence in a cell suspended in a fluid comprising a means for fixing the suspended cell and a nucleotide probe complementary to a nucleotide sequence within the suspended cell.
21. The kit of claim 20, further comprising a means for detecting the hybridized probe.
22. A method of detecting a specific nucleotide sequence in nucleic acid in a cell suspended in a fluid, comprising:
a. fixing the suspended cell in such a way as to permit a nucleotide probe to penetrate without disrupting the suspended cell;
b. denaturing the nucleic acid in the cell;
c. providing a nucleotide probe complementary to the specific nucleotide sequence within the suspended cell under conditions permitting hybridization; and
d. detecting hybridized probe within the cell, whereby hybridized probe indicates the presence of the specific nucleotide sequence.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31998289A | 1989-03-07 | 1989-03-07 | |
US319,982 | 1989-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990010715A1 true WO1990010715A1 (en) | 1990-09-20 |
Family
ID=23244366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/001191 WO1990010715A1 (en) | 1989-03-07 | 1990-03-05 | In-situ hybridization in suspension for detection or separation of cells |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0462221A1 (en) |
JP (1) | JPH04505556A (en) |
AU (1) | AU646635B2 (en) |
CA (1) | CA2011571A1 (en) |
WO (1) | WO1990010715A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019967A1 (en) * | 1991-05-03 | 1992-11-12 | Ig Laboratories, Inc. | Method for obtaining informative cells |
WO1993004197A1 (en) * | 1991-08-13 | 1993-03-04 | Universitaire Instelling Antwerpen | Method for detecting a virus in cell material of a scrape or body fluid |
WO1994002646A1 (en) * | 1992-07-17 | 1994-02-03 | Aprogenex Inc. | Enriching and identyfying fetal cells in maternal blood for in situ hybridization |
WO1995003428A1 (en) * | 1993-07-20 | 1995-02-02 | University Of Massachusetts Medical Center | In vivo nucleic acid hybridization method |
WO1996004402A1 (en) * | 1994-08-05 | 1996-02-15 | The Regents Of The University Of California | Detection of mycobacteria |
US5501952A (en) * | 1992-07-17 | 1996-03-26 | Aprogenex, Inc. | Analogues of reporter groups as background reducers in hybridization assays |
US5521061A (en) * | 1992-07-17 | 1996-05-28 | Aprogenex, Inc. | Enhancement of probe signal in nucleic acid-mediated in-situ hybridization studies |
WO1996036734A1 (en) * | 1995-05-18 | 1996-11-21 | Abbott Laboratories | Polymeric peptide probes and uses thereof |
US5582982A (en) * | 1992-07-17 | 1996-12-10 | Aprogenex, Inc. | Background-reducing compounds for probe-mediated fluorimetric flow cytometric assays |
US5888733A (en) * | 1995-11-16 | 1999-03-30 | Dako A/S | In situ hybridization to detect specific nucleic acid sequences in eucaryotic samples |
US5985563A (en) * | 1994-05-19 | 1999-11-16 | Dako A/S | Detection of Ribosomal RNA using PNA probes |
US6200762B1 (en) | 1997-08-01 | 2001-03-13 | Aurora Biosciences Corporation | Photon reducing agents and compositions for fluorescence assays |
US6214563B1 (en) | 1997-08-01 | 2001-04-10 | Aurora Biosciences Corporation | Photon reducing agents for reducing undesired light emission in assays |
US6221612B1 (en) | 1997-08-01 | 2001-04-24 | Aurora Biosciences Corporation | Photon reducing agents for use in fluorescence assays |
US6610475B1 (en) | 1993-02-10 | 2003-08-26 | Gen-Probe Incorporated | Kits for processing biological specimens for nucleic acid hybridization assays, target amplification reactions and similar uses |
WO2003091449A1 (en) * | 2002-04-26 | 2003-11-06 | Riken | Method of measuring neprilysin activity |
EP1461453A2 (en) * | 2001-11-30 | 2004-09-29 | Amnis Corporation | Methods of identifying cellular target molecules |
WO2006012302A2 (en) * | 2004-06-28 | 2006-02-02 | Exagen Diagnostics, Inc. | Methods for rna fluorescence in situ hybridization |
US7925069B2 (en) | 1999-01-25 | 2011-04-12 | Amnis Corporation | Blood and cell analysis using an imaging flow cytometer |
US8406498B2 (en) | 1999-01-25 | 2013-03-26 | Amnis Corporation | Blood and cell analysis using an imaging flow cytometer |
US8548219B2 (en) | 1999-01-25 | 2013-10-01 | Amnis Corporation | Detection of circulating tumor cells using imaging flow cytometry |
US8885913B2 (en) | 1999-01-25 | 2014-11-11 | Amnis Corporation | Detection of circulating tumor cells using imaging flow cytometry |
US8953866B2 (en) | 2004-03-16 | 2015-02-10 | Amnis Corporation | Method for imaging and differential analysis of cells |
US9528989B2 (en) | 2004-03-16 | 2016-12-27 | Amnis Corporation | Image-based quantitation of molecular translocation |
CN107748256A (en) * | 2017-10-11 | 2018-03-02 | 上海医盈网络科技有限公司 | A kind of liquid biopsy detection method of circulating tumor cell |
US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
US11299764B2 (en) | 2015-11-20 | 2022-04-12 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68928080T2 (en) * | 1988-08-31 | 1998-01-15 | Aprogenex Inc | ONE-STEP IN SITU HYBRID TEST PROCEDURE |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4038143A (en) * | 1973-10-29 | 1977-07-26 | The Regents Of The University Of Michigan | Test kit for the genetic detection of microorganisms |
GB2139349A (en) * | 1983-04-29 | 1984-11-07 | Nat Res Dev | Method of determining nucleotide sequences in cells and of isolating nucleic acids from cells |
WO1985004720A1 (en) * | 1984-04-05 | 1985-10-24 | Howard Florey Institute Of Experimental Physiology | Hybridization histochemistry |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68928080T2 (en) * | 1988-08-31 | 1998-01-15 | Aprogenex Inc | ONE-STEP IN SITU HYBRID TEST PROCEDURE |
-
1990
- 1990-03-05 JP JP2505226A patent/JPH04505556A/en active Pending
- 1990-03-05 WO PCT/US1990/001191 patent/WO1990010715A1/en not_active Application Discontinuation
- 1990-03-05 EP EP90905309A patent/EP0462221A1/en not_active Withdrawn
- 1990-03-05 AU AU52899/90A patent/AU646635B2/en not_active Expired - Fee Related
- 1990-03-06 CA CA002011571A patent/CA2011571A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4038143A (en) * | 1973-10-29 | 1977-07-26 | The Regents Of The University Of Michigan | Test kit for the genetic detection of microorganisms |
GB2139349A (en) * | 1983-04-29 | 1984-11-07 | Nat Res Dev | Method of determining nucleotide sequences in cells and of isolating nucleic acids from cells |
EP0127327A1 (en) * | 1983-04-29 | 1984-12-05 | National Research Development Corporation | Method of determining nucleotide sequences in cells and of isolating nucleic acids from cells |
WO1985004720A1 (en) * | 1984-04-05 | 1985-10-24 | Howard Florey Institute Of Experimental Physiology | Hybridization histochemistry |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992019967A1 (en) * | 1991-05-03 | 1992-11-12 | Ig Laboratories, Inc. | Method for obtaining informative cells |
WO1993004197A1 (en) * | 1991-08-13 | 1993-03-04 | Universitaire Instelling Antwerpen | Method for detecting a virus in cell material of a scrape or body fluid |
BE1005174A3 (en) * | 1991-08-13 | 1993-05-11 | Universitaire Instelling Antwe | METHOD FOR DETECTION OF A VIRUS IN A cellular material from scrapings or bodily fluids. |
US5501952A (en) * | 1992-07-17 | 1996-03-26 | Aprogenex, Inc. | Analogues of reporter groups as background reducers in hybridization assays |
US5521061A (en) * | 1992-07-17 | 1996-05-28 | Aprogenex, Inc. | Enhancement of probe signal in nucleic acid-mediated in-situ hybridization studies |
US5582982A (en) * | 1992-07-17 | 1996-12-10 | Aprogenex, Inc. | Background-reducing compounds for probe-mediated fluorimetric flow cytometric assays |
WO1994002646A1 (en) * | 1992-07-17 | 1994-02-03 | Aprogenex Inc. | Enriching and identyfying fetal cells in maternal blood for in situ hybridization |
US6610475B1 (en) | 1993-02-10 | 2003-08-26 | Gen-Probe Incorporated | Kits for processing biological specimens for nucleic acid hybridization assays, target amplification reactions and similar uses |
WO1995003428A1 (en) * | 1993-07-20 | 1995-02-02 | University Of Massachusetts Medical Center | In vivo nucleic acid hybridization method |
US5728527A (en) * | 1993-07-20 | 1998-03-17 | University Of Massachusetts Medical Center | Detection of hybridized oligonocleotide probes in living cells |
US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
US5985563A (en) * | 1994-05-19 | 1999-11-16 | Dako A/S | Detection of Ribosomal RNA using PNA probes |
WO1996004402A1 (en) * | 1994-08-05 | 1996-02-15 | The Regents Of The University Of California | Detection of mycobacteria |
US5582985A (en) * | 1994-08-05 | 1996-12-10 | The Regents Of The University Of California | Detection of mycobacteria |
WO1996036734A1 (en) * | 1995-05-18 | 1996-11-21 | Abbott Laboratories | Polymeric peptide probes and uses thereof |
US5888733A (en) * | 1995-11-16 | 1999-03-30 | Dako A/S | In situ hybridization to detect specific nucleic acid sequences in eucaryotic samples |
US8518710B2 (en) | 1997-08-01 | 2013-08-27 | Life Technologies Corporation | Photon reducing agents for fluorescence assays |
US7067324B2 (en) | 1997-08-01 | 2006-06-27 | Invitrogen Corporation | Photon reducing agents for fluorescence assays |
US6214563B1 (en) | 1997-08-01 | 2001-04-10 | Aurora Biosciences Corporation | Photon reducing agents for reducing undesired light emission in assays |
US6221612B1 (en) | 1997-08-01 | 2001-04-24 | Aurora Biosciences Corporation | Photon reducing agents for use in fluorescence assays |
US6200762B1 (en) | 1997-08-01 | 2001-03-13 | Aurora Biosciences Corporation | Photon reducing agents and compositions for fluorescence assays |
US8163562B2 (en) | 1997-08-01 | 2012-04-24 | Life Technologies Corporation | Photon reducing agents for fluorescence assays |
US7785536B2 (en) | 1997-08-01 | 2010-08-31 | Life Technologies Corporation | Photon reducing agents for fluorescence assays |
US8660332B2 (en) | 1999-01-25 | 2014-02-25 | Amnis Corporation | Blood and cell analysis using an imaging flow cytometer |
US8885913B2 (en) | 1999-01-25 | 2014-11-11 | Amnis Corporation | Detection of circulating tumor cells using imaging flow cytometry |
US8548219B2 (en) | 1999-01-25 | 2013-10-01 | Amnis Corporation | Detection of circulating tumor cells using imaging flow cytometry |
US7925069B2 (en) | 1999-01-25 | 2011-04-12 | Amnis Corporation | Blood and cell analysis using an imaging flow cytometer |
US8406498B2 (en) | 1999-01-25 | 2013-03-26 | Amnis Corporation | Blood and cell analysis using an imaging flow cytometer |
EP1461453A2 (en) * | 2001-11-30 | 2004-09-29 | Amnis Corporation | Methods of identifying cellular target molecules |
EP1461453A4 (en) * | 2001-11-30 | 2004-12-15 | Amnis Corp | Methods of identifying cellular target molecules |
WO2003091449A1 (en) * | 2002-04-26 | 2003-11-06 | Riken | Method of measuring neprilysin activity |
US7572574B2 (en) | 2002-04-26 | 2009-08-11 | Riken | Method of measuring neprilysin activity |
US8953866B2 (en) | 2004-03-16 | 2015-02-10 | Amnis Corporation | Method for imaging and differential analysis of cells |
US9528989B2 (en) | 2004-03-16 | 2016-12-27 | Amnis Corporation | Image-based quantitation of molecular translocation |
WO2006012302A2 (en) * | 2004-06-28 | 2006-02-02 | Exagen Diagnostics, Inc. | Methods for rna fluorescence in situ hybridization |
WO2006012302A3 (en) * | 2004-06-28 | 2006-05-04 | Exagen Diagnostics Inc | Methods for rna fluorescence in situ hybridization |
US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
US11299764B2 (en) | 2015-11-20 | 2022-04-12 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
CN107748256A (en) * | 2017-10-11 | 2018-03-02 | 上海医盈网络科技有限公司 | A kind of liquid biopsy detection method of circulating tumor cell |
Also Published As
Publication number | Publication date |
---|---|
EP0462221A1 (en) | 1991-12-27 |
AU646635B2 (en) | 1994-03-03 |
AU5289990A (en) | 1990-10-09 |
JPH04505556A (en) | 1992-10-01 |
CA2011571A1 (en) | 1990-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU646635B2 (en) | In-situ hybridization in suspension for detection or separation of cells | |
US5985549A (en) | Non-isotopic in-situ hybridization method for detection of nucleic acids | |
EP0420260B1 (en) | Method and kit for detecting a target nucleic acid using a capture probe bound to a polystyrene support via an intermediary protein. | |
EP0524808B1 (en) | In situ PCR preparations and use. | |
EP0614492B1 (en) | In situ hybridization method | |
US6054266A (en) | Nucleic acid detection with separation | |
EP0322311B1 (en) | Method and kit for detecting a nucleic acid sequence | |
AU2004257200A1 (en) | Hairpin-labeled probes and methods of use | |
JPH04506599A (en) | Methods for detecting specific nucleic acid sequences and their applications | |
CA2031659A1 (en) | Water-insoluble reagent, nucleic acid probe, test kit and diagnostic and purification methods | |
EP0436547B1 (en) | Process for rapid nucleic acid detection | |
JP3495752B2 (en) | Live target individual detection method and probe | |
EP0432221B1 (en) | One-step in situ hybridization assay | |
US6242184B1 (en) | In-situ hybridization of single-copy and multiple-copy nucleic acid sequences | |
JPH10500313A (en) | Detection of nucleic acids in cells by thermophilic strand displacement amplification | |
US5792609A (en) | Detection of malaria | |
JPH05501961A (en) | New pathogen detection method using DNA probes | |
US20050272032A1 (en) | Internal control for in situ hybridization | |
CA2024978A1 (en) | Nucleic acid detection method using unequal primer concentrations in polymerase chain reaction | |
JPH07298897A (en) | Method for formation,amplification and detection of target nucleic acid using two labeling primers and pcr kit containing said nucleic acid | |
EP0249628A1 (en) | Method, kit and product for disease diagnosis | |
GB2242904A (en) | Detection of pathogens using DNA probes | |
Singer et al. | Diagnostic applications of nonisotopic in situ hybridization of HIV or EBV nucleic acids | |
PINKEL et al. | JGJ BAUMAN | |
GB2271850A (en) | Non-radioactive hybridisation assay for pathogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990905309 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990905309 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990905309 Country of ref document: EP |